Search

A 10-year-old girl experienced a rebound effect after discontinuing colchicine for PFAPA syndrome, resulting in a relapse of orogenital ulcers and high-grade fever. The girl had a history of periodic high fever and oral aphthosis, leading to a diagnosis of PFAPA syndrome. Treatment with prednisolone and corticosteroids provided relief, but when colchicine was discontinued, the girl experienced a relapse of symptoms. Re-initiating colchicine therapy led to a normalization of fever without recurrence of orogenital ulcers. [Extracted from the article]

A 33-year-old man with HTLV-1-associated adult T-cell lymphoma/leukemia (ATLL) experienced thrombocytopenia and stomatitis while being treated with pralatrexate. He also showed lack of efficacy with zidovudine and Interferon-alpha-2b. The patient had previously received radiation therapy and chemotherapy, which led to disease resolution, but experienced a relapse and started on zidovudine and Interferon-alpha-2b therapy. After enrolling in a phase 2 study, he received a single dose of pralatrexate, which resulted in adverse effects but also showed a positive response in treating his ATLL. His clinical condition subsequently improved. [Extracted from the article]

A retrospective chart review study described seven patients who developed stomatitis during treatment with panitumumab for metastatic colorectal cancers. The patients ranged in age from 37 to 68 years and included four women and three men. Stomatitis is a condition characterized by ulcers and lesions in the mouth. The severity of stomatitis varied among the patients, with grades ranging from 2 to 3. Treatment options included medications such as sodium bicarbonate, clobetasol, and prednisone, as well as photobiomodulation. Complete remission of stomatitis was achieved in all cases. [Extracted from the article]

Case 1 from the article: A 45-year-old woman exhibited lack of efficacy following treatment with afatinib, aumolertinib, carboplatin, paclitaxel and tislelizumab for metastatic lung squamous cell carcinoma. She underwent right thoracoscopic exploration, wedge-shaped resection of the upper lobe of the right lung, intraoperative freezing, resection of the upper lobe of the right lung and mediastinal lymph node dissection. [Extracted from the article]

The steady state trough concentration was 8.4 ng/mL after restarting everolimus. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a prospective, observational, pharmacokinetic (PK) study conducted in Japan between November 2015 and November 2018 involving 18 patients, et al. 65-year-old woman and a 64-year-old woman were described who developed stomatitis and exhibited lack of efficacy during treatment with everolimus for metastatic breast cancer [ I routes not stated; not all time to reactions onsets stated i ]. [Extracted from the article]

At the age of 41 years, she was diagnosed with Dukes-C sigmoid cancer and underwent resection, followed by adjuvant chemotherapy with fluorouracil [5-fluorouracil], folinic acid [leucovorin] and oxaliplatin. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study of 2 patients, et al. 41-year-old woman was described, who developed neutropenia with fever and stomatitis during treatment with oxaliplatin, fluorouracil and folinic acid for Dukes-C sigmoid cancer [ I routes, dosages, duration of treatments to reaction onsets and outcomes not stated i ]. However, she developed neutropenia with fever and stomatitis secondary to fluorouracil, folinic acid and oxaliplatin. [Extracted from the article]

However, she developed stomatitis and recurrent infections, secondary to the sirolimus therapy. As a result, her platelet count and fibrinogen level normalised within several weeks. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a case series, a 7-Year-old girl developed stomatitis and recurrent infections during treatment with sirolimus for Kaposiform lymphangiomatosis (KLA) [ I dosage, route, duration of treatment to reaction onset and outcome not stated i ]. [Extracted from the article]

She was successfully treated with prednisolone; however, purpuric eruptions relapsed after reducing the dose of prednisolone (rebound purpuric eruptions). B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 62-year-old woman developed stomatitis and inappetence during treatment with methotrexate for rheumatoid arthritis. [Extracted from the article]

Hence, in May 2012, he received neoadjuvant chemotherapy with a combination of high-dose methotrexate, cisplatin and doxorubicin [MAP regimen; I routes and dosages not stated i ] for three months. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 10-year-old boy developed stomatitis, low Hb and neutropenia during treatment with methotrexate, cisplatin and doxorubicin for chondroblastic osteosarcoma. [Extracted from the article]

A 70-year-old woman developed stomatitis during treatment with gefitinib, and cardiomyopathy during treatment with erlotinib for advanced metastatic non-small cell lung cancer [NSCLC; I not all outcomes stated; durations of treatments to reactions onsets not stated i ]. T2-weighted short-tau inversion recovery images did not show evidence of myocardial oedema. She was continued on unspecified treatment for heart failure and cardiac function was maintained until the end of the follow-up period. [Extracted from the article]

The cause of death was therefore concluded to be due to severe anaemia, frailty, respiratory failure associated with pleural effusion and cardiac failure associated with hypoproteinaemia and severe anaemia. Blood tests revealed leukopenia and microcytic hypochromic anaemia with decreased reticulocytes. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An 84-year-old woman developed stomatitis during treatment with methotrexate and gelatinous transformation of the bone marrow during treatment with methotrexate and celecoxib for rheumatoid arthritis. [Extracted from the article]

During the subsequent years, bilateral renal angiomyolipoma and sub-ependymal giant cell astrocytoma associated with tuberous sclerosis complex were diagnosed. Dose of everolimus was reduced following episodes of aphthous stomatitis; while everolimus was temporarily interrupted during treatment of the febrile episode with zoster-like cutaneous rash on the lower extremity at clinic [ I outcomes not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 21-year-old woman developed aphthous stomatitis and febrile cutaneous rash on lower extremity during treatment with everolimus for bilateral renal angiomyolipoma and sub-ependymal giant cell astrocytoma associated with tuberous sclerosis complex. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A woman in her 80s [ I exact age not stated i ] developed stomatitis during treatment with off-label pralatrexate for relapsed refractory nodal peripheral T-cell lymphoma. She was diagnosed with T-cell lymphoma and received treatment with off-label CHOP therapy consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study of 196 patients with HER-2 positive breast cancer, four patients [ I ages and sexes not stated i ] were described, of whom three patients developed infusion related reaction and one patient developed stomatitis during treatment with trastuzumab for HER-2 positive breast cancer. The patients, who had HER-2 positive breast cancer, started receiving treatment with trastuzumab biosimilars infusion [ I dosages not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A man in late 70s' developed stomatitis during treatment with everolimus and febrile neutropenia during treatment with amrubicin for carcinoma. The man presented (at the age of 74 years) for treatment of small cell carcinoma of the bladder. His medical history was significant for thyroid cancer, left adrenal pheochromocytoma, cigarette smoking, occasion intake of alcohol, had undergone transurethral resection of the bladder tumour in December 2015. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 49-year-old man developed DRESS syndrome during treatment with carbamazepine, escitalopram and amoxicillin [ I routes not stated; not all dosages and duration of treatments to reaction onsets stated i ]. The possible suspected diagnoses were acute oedema of epiglottis following an allergic reaction or DRESS syndrome. Considering the possibility of DRESS syndrome, his carbamazepine was stopped and treatment for depression with alcohol addiction was changed to valproic acid with continued zolpidem and diazepam. [Extracted from the article]

A 47-year-old man developed stomatitis and neutropenia during treatment with docetaxel for metastatic primary pulmonary hepatoid adenocarcinoma. The man, who was diagnosed with stage IV metastatic primary pulmonary hepatoid adenocarcinoma with normal serum -fetoprotein level, started receiving chemotherapy with cisplatin and etoposide. After two cycles of docetaxel therapy, his tumour shrank; however, he developed severe stomatitis and neutropenia [ I durations of treatment to reactions onset not stated i ]. [Extracted from the article]

A 61-year-old man developed acneiform rash and anterior stomatitis during treatment with cetuximab for locally invasive nasopharyngeal carcinoma. Additionally, he developed radiation-related dysphagia and odynophagia. Due to declining oral intake and weight loss (resulting from dysphagia and odynophagia), a feeding tube was placed one-third of the way through the man's treatment course in hospital. [Extracted from the article]

A man in his 60s [ I age at the time of reaction onset not clearly stated i ] developed stomatitis during treatment with bendamustine, rituximab and venetoclax for chronic lymphocytic leukaemia (CLL), and developed lower extremity rash during treatment with ibrutinib for leptomeningeal carcinomatosis [ I routes, time to reactions onsets and outcomes not stated; not all dosages stated i ]. B Author comment: b I "At this time, he developed leukocytosis and was started on bendamustine, rituximab, and venetoclax...This treatment was poorly tolerated because of severe stomatitis.". [Extracted from the article]

A 45-year-old woman developed stomatitis and low back pain during treatment with cyclophosphamide, docetaxel and doxorubicin for stage IIb invasive ductal breast carcinoma. There was no event of drug washout or dose-reduction during the sixth course, and the only side-effects were grade 2 low back pain and stomatitis. There was no event of dose reduction or drug washout during the 6th course, and the only side effects were stomatitis and low back pain (grade 2). [Extracted from the article]

A 38-year-old man developed delayed type hypersensitivity in the form of contact stomatitis during treatment with buprenorphine/naloxone for opioid use disorder. The man, who had a history of complex regional pain syndrome along with opioid use disorder, was receiving sublingual buprenorphine/naloxone [Suboxone] [ I dosage not stated i ] therapy for one month. After consultation with pain management and otolaryngology teams, his sublingual buprenorphine/naloxone therapy was changed to buprenorphine transdermal patch due to a possibility of delayed type hypersensitivity in the form of contact stomatitis secondary to buprenorphine/naloxone. [Extracted from the article]

The article presents case studies of a 84-year-old man, 83-year-old woman and 78-year-old man with medical histories bullous pemphigoid and arterial hypertension.

The article presents a case study of three patients having stomatitis after treatment with ibrutinib for chronic lymphocytic leukaemia (CLL).

The article presents a case study of a 34-year-old woman who was treated with sirolimus for lymphangioleiomyomatosis and subsequently developed stomatitis which did not require drug treatment.

The article presents a case study of a 64 year old man suffering from bipolar disorder, developing stomatitis during the treatment with lamotrigine.

The article presents case studies of five women of whom two developed stomatitis, two developed interstitial pneumonia and one woman developed thrombocytopenia during treatment with everolimus for ER positive, HER2 negative breast cancer.

The article presents a case study of 14 patients who experienced grade 3 adverse event of stomatitis while being medicated with everolimus for tuberous sclerosis.

The article presents a case study of a patient who developed stomatitis during treatment with everolimus for angiomyolipoma.

The article presents case studies of two elderly patients, one developed fatigue and the other developed stomatitis, while receiving osimertinib for the treatment of non-small cell lung cancer.

This article presents a case study of three patients, one of whom developed infection, one of whom developed stomatitis, and one of whom developed acute kidney injury, after treatment for anal squamous cell carcinoma with mitomycin, flurouracil, or capecitabine.